Vertex Pharmaceuticals Incorporated (VRTX) : The money flow analysis of Vertex Pharmaceuticals Incorporated (VRTX) indicates a $11.94 million of outflow was on downticks, whereas, the investors on Friday gobbled up stocks worth $14.08 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.18 and so was the total money flow at $2.14 million. A solid up-down ratio of 1.71 in block trades indicates that the investors are accumulating the stock on weakness. The bulls lapped up $3.58 million worth of block trades on upticks. Only $2.09 million worth of the stock exchanged hands on downticks. The money flow was $1.49 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Vertex Pharmaceuticals Incorporated (VRTX), pushing it down by -0.19% for the day. The stock slid $0.18 and traded at $94.57 during the day. Nonetheless, the stock is -2.6% over the previous weeks close.
The company Insiders own 1.9% of Vertex Pharmaceuticals Incorporated shares according to the proxy statements. Institutional Investors own 96.36% of Vertex Pharmaceuticals Incorporated shares. During last six month period, the net percent change held by insiders has seen a change of -3.03%.
In a related news, The Securities and Exchange Commission has divulged that Boger Joshua S, director of Vertex Pharmaceuticals Inc / Ma, had unloaded 6,500 shares at an average price of $94.9 in a transaction dated on August 31, 2016. The total value of the transaction was worth $616,850.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): The stock opened at $94.76 and touched an intraday high of $95.54 on Friday. During the day, the stock corrected to an intraday low of $93.6547, however, the bulls stepped in and pushed the price higher to close in the green at $95.11 with a gain of 0.38% for the day. The total traded volume for the day was 843,132. The stock had closed at $94.75 in the previous trading session.
Vertex Pharmaceuticals Incorporated (VRTX) : During the past 4 weeks, traders have been relatively bearish on Vertex Pharmaceuticals Incorporated (VRTX), hence the stock is down -7.02% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.53% relative to the S&P 500. The 4-week change in the price of the stock is -7.15% and the stock has fallen -2.04% in the past 1 week.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.